CRISPRMED25 - Interview: Avencia Sánchez-Mejías (Integra Therapeutics)

Intellia Therapeutics has reported positive three-year follow-data from the ongoing Phase 1/2 trial of lonvo-z (formerly known as NTLA-2002) in...

Eli Lilly announced today that it will acquire Verve Therapeutics for up to $1.3 billion to develop single-dose base-editing treatments for people...

Chinese researchers have developed a thermosensitive, polyamine-modified hydrogel that significantly improves the co-delivery of CRISPR/Cas9 gene...

Some of the best links we picked up around the internet

SNIPR Biome has dosed the first patient in its Phase 1b trial of SNIPR001, a CRISPR-CAS-armed bacteriophage therapy that represents a new frontier in...

A new computational framework called CCLMoff uses deep learning and RNA language models to predict off-target effects in CRISPR-CAS9 genome editing...